Results 31 to 40 of about 82,830 (185)

Importance of hematocrit for a tacrolimus target concentration strategy [PDF]

open access: yes, 2013
Purpose To identify patient characteristics that influence tacrolimus individual dose requirement in kidney transplant recipients. Methods Data on forty-four 12-h pharmacokinetic profiles from 29 patients and trough concentrations in 44 patients measured
Midtvedt, Karsten   +11 more
core   +1 more source

Comparative Study of the Cellular Pharmacodynamics of Tacrolimus in Renal Transplant Recipients Treated with and without Basiliximab

open access: yesCell Transplantation, 2012
Basiliximab is a recently developed immunosuppressive agent for the prevention of acute allograft rejection in renal transplant recipients. The combination use of basiliximab and a calcineurin inhibitor was suggested to be more effective in comparison to
Kentaro Sugiyama Ph.D.   +9 more
doaj   +1 more source

Effects of the CYP3A4*1B Genetic Polymorphism on the Pharmacokinetics of Tacrolimus in Adult Renal Transplant Recipients: A Meta-Analysis. [PDF]

open access: yesPLoS ONE, 2015
BACKGROUND AND OBJECTIVE:The association between the CYP3A4*1B single nucleotide polymorphism (SNP) and tacrolimus pharmacokinetics in different studies is controversial.
Wei-Long Shi, Hui-Lin Tang, Suo-Di Zhai
doaj   +1 more source

Variability of Tacrolimus Trough Concentration in Liver Transplant Patients: Which Role of Inflammation?

open access: yesPharmaceutics, 2021
Tacrolimus presents high intra and inter-individual variability in its blood trough concentration (Cmin). Knowledge of the factors that are involved in tacrolimus Cmin variability is thus clinically important to prevent or limit it.
Anaelle Chavant   +5 more
doaj   +1 more source

A case report: acute pancreatitis associated with tacrolimus in kidney transplantation

open access: yesBMC Nephrology, 2019
Background Tacrolimus has been widely used for immunosuppressive therapy in solid organ transplantation (SOT) and allo-geneic stem cell transplantation (allo-SCT) over the past 2 decades.
Junnan Xu   +4 more
doaj   +1 more source

Pharmacokinetics of Tacrolimus in Egyptian Liver Transplant Recipients: Role of the Classic Co-variables [PDF]

open access: yesJournal of Advanced Pharmacy Research, 2019
Objectives: This work was performed to study the pharmacokinetics of tacrolimus in adult liver transplant recipients after optimization of all the known classic factors contributing to inter-patient variability in whole blood tacrolimus levels.
Abdel-hamid Ebid   +3 more
doaj   +1 more source

Estudo do tacrolimus sobre a resposta inflamatória induzida pela carragenina no modelo da bolsa de ar, em camundongos [PDF]

open access: yes, 2008
Dissertação (mestrado) - Universidade Federal de Santa Catarina, Centro de Ciências da Saúde. Programa de Pós-Graduação em Farmácia.Introdução: Tacrolimus é um imunossupressor da classe dos macrolídeos utilizado na clínica para evitar a regeição em ...
Vigil, Silvana Virginia Gagliotti
core  

Tacrolimus for the Treatment of Ulcerative Colitis [PDF]

open access: yesIntestinal Research, 2015
Tacrolimus is a calcineurin inhibitor used for the treatment of corticosteroid-refractory ulcerative colitis (UC). Two randomized controlled trials and a number of retrospective studies have assessed the therapeutic effect of tacrolimus in UC patients ...
Katsuyoshi Matsuoka   +7 more
doaj   +1 more source

Estudo do efeito antiinflamatório do tacrolimus no modelo de pleurisia, em camundongos [PDF]

open access: yes, 2006
Dissertação (mestrado) - Universidade Federal de Santa Catarina, Centro de Ciências da Saúde. Programa de Pós-Graduação em Ciências Médicas.Introdução: O tacrolimus é um agente imunossupressor isolado do Streptomyces tsukubaensis e é utilizado ...
Pereira, Robson Roman
core  

Hemoglobin and total bilirubin may affect tacrolimus clearance in liver transplant patient following the early postoperative period: a case report

open access: yesJournal of Medical Case Reports
Background Tacrolimus is a potent calcineurin inhibitor (CNI) that is principally used as a first-line immunosuppressant for the prophylaxis of allograft rejection in liver transplantation (LT) patients.
Vichapat Tharanon   +5 more
doaj   +1 more source

Home - About - Disclaimer - Privacy